How would you propose to identify a CSF-, blood-, or urine-based biomarker to stratify early Parkinson’s disease patients according to the degree of lysosomal dysfunction? A new opn2EXPERTS call on opnMe, inviting researchers to submit innovative proposals addressing this question. Selected proposals will be reviewed by Boehringer Ingelheim’s Neuroscience Research experts who will award funding and collaboration opportunities to advance biomarker-driven approaches in Parkinson’s disease. Deadline for applications 01 Sep, 2026 Further information and application
